Co-Founder and CEO of Phagos, Alexandros Pantalis is a serial tech entrepreneur who has raised over €25 million from leading venture capital firms to support the growth of innovative start-ups. He began his career in transaction advisory at EY after graduating from HEC Paris, and now leads Phagos in its mission to revolutionize infectious disease treatment through AI and phage science.
Este nuevo modelo permite actualizar continuamente las formulaciones de fagos para combatir la resistencia a los antibióticos y podría servir como un modelo para su adopción a nivel mundial.
This new model allows for continually updated phage formulations to combat resistance to antibiotics and could serve as a blueprint for global adoption.
Se prevé que la resistencia a los antimicrobianos causará 10 millones de muertes al año para 2050. La terapia con bacteriófagos podría ayudar a contrarrestar ese problema.
Antimicrobial resistance is set to cause 10 million annual deaths by 2050. Bacteriophage therapy can help fill the void left by a lack of new antibiotics.
